From the first day, SK Bioscience went directly to the high-end price and entered the stock market splendidly.



As of today (18th) 10:05 am, SK Bioscience is trading at 169,000 won in the stock market, up to the price limit (30.00%) compared to the initial price of 130,000 won.



The initial price of the listing date was decided at twice the price of the public offering, and the so-called'dasang', which soared to the upper limit price, was successful.



The share price based on'Daesang' exceeds the public offering price of 65,000 won by 160%, and the public offering investor's return is 104,000 won per share.



SK Biosciences jumped to the upper limit at the same time as it was listed, and immediately after the opening, the static and dynamic volatility mitigation device (VI) was triggered due to a surge in stock prices.



At this time, the number of stocks waiting to be bought at the intraday ceiling is about 6.6 million shares.



Immediately after listing, SK Bioscience's market capitalization increased to 12.92 trillion won, quickly becoming 28th in the KOSPI market cap.



As of the current market cap, it surpassed SK Biopharm (8 trillion KRW) and Big Hit (8 trillion KRW), which were listed last year and became popular.



SK Bioscience, which has been regarded as an IPO in the first half of this year, predicted a surge in stock prices in the early stage of listing by making progress in demand forecasts for institutional investors and general subscriptions.



In particular, the number of shares available for circulation on the date of listing was as low as 11.63% of the total issued stocks, so the expectation was high.



SK Biosciences is a vaccine company established by spin-off from SK Chemicals in 2018.As of 2019, sales amounted to KRW 183.9 billion and net income was KRW 14.7 billion.



(Photo = Yonhap News)